Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
17.5M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
6.29M
-
Shares change
-
+1.14M
-
Total reported value, excl. options
-
$27.4M
-
Value change
-
+$4.97M
-
Number of buys
-
22
-
Number of sells
-
-4
-
Price
-
$4.36
Significant Holders of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value (UNCY) as of Q3 2025
33 filings reported holding UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q3 2025.
Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value (UNCY) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.29M shares
of 17.5M outstanding shares and own 35.83% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (1.79M shares), Octagon Capital Advisors LP (1M shares), Nantahala Capital Management, LLC (939K shares), GREAT POINT PARTNERS LLC (797K shares), VANGUARD GROUP INC (659K shares), Logos Global Management LP (474K shares), GEODE CAPITAL MANAGEMENT, LLC (126K shares), Squarepoint Ops LLC (117K shares), ACUTA CAPITAL PARTNERS, LLC (60K shares), and STATE STREET CORP (54.8K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.